Background: Topical imiquimod has been used as a skin‐directed treatment in selected patients with mycosis fungoides, but the available evidence remains limited and scattered across case reports, case series, pilot studies, retrospective cohorts, and preliminary conference data. Objective: To systematically review the published clinical evidence on topical imiquimod in mycosis fungoides, with emphasis on treatment settings, regimens, outcomes, tolerability, and durability of response. Methods: A systematic review was performed according to PRISMA principles. PubMed and Scopus were searched from database inception to April 2026 to identify publications reporting topical imiquimod use in histopathologically confirmed mycosis fungoides. Eligible publications included case reports, case series, pilot studies, retrospective cohorts, and conference abstracts with extractable imiquimod‐specific clinical outcome data. Because of marked heterogeneity in study design, disease stage, treatment schedules, follow‐up duration, and outcome reporting, the data were synthesized qualitatively. Results: Fifteen studies comprising 47 imiquimod‐treated patients or patients with MF‐related entities were included. Evidence consisted mainly of individual case reports and small case series, supplemented by pilot studies, retrospective cohorts, and one recent conference Topical imiquimod was most commonly used for localized, treatment‐refractory, or anatomically challenging lesions, including plaque‐stage, folliculotropic, and tumor‐stage mycosis fungoides. Clinical improvement, including complete or near‐complete clearance in selected reports, was described most often in localized or refractory disease. In larger observational studies, reported overall response rates were more modest, ranging from approximately 50%–60%, with complete clearance reported in 40% in one recent cohort. Local inflammatory reactions were commonly reported; however, their association with clinical improvement remains observational and cannot be interpreted as evidence of causality. Conclusions: Topical imiquimod may represent a potential individualized skin‐directed approach for selected patients with localized or treatment‐refractory mycosis fungoides. However, the current evidence remains limited, heterogeneous, predominantly low level, and subject to publication bias.